Thirty years in carbohydrate and small molecule chemistry.

More than three decades in industry have helped us build a high-level of expertise. Combined with our focus on quality and customer service, we believe we have something special to offer our clients.

Our successful discovery work with international partners has placed us at the forefront of drug development for some of the world’s most serious diseases.

From this strong base, we have built an impressive track record from early-stage research through to the chemical synthesis and small-scale manufacture of drug compounds for pre-clinical and clinical trials.


Some of our highlights:

  • Over thirty years of experience in complex carbohydrate chemistry, over a decade of ICH Q7-equivalent cGMP manufacture
  • Our clients range from NASDAQ Pharma companies through to biotech start-ups
  • Consistently delivered product to meet client needs
  • Delivered compounds and data resulting in successful IND submissions
  • Engaged in late-stage development/validation of recent processes


What our customers have to say:



"GlycoSyn not only have excellent facilities supported by world-class staff but importantly from a client’s perspective, understand the pharmaceutical industry needs and demanding standards from laboratory work through to process design and scale-up under GMP. This, together with not only a “can do” but a “will do” attitude, has significantly contributed to our ongoing success.”

-Dr Philip Marshall, CEO, Oncology Research International LImited





“I've had the great fortune to work with GlycoSyn for over 10 years now, on projects that span my time at Spinifex Pharmaceutical and Starpharma. In all their work for me they have demonstrated a very high level of technical proficiency as they developed scalable synthetic routes to APIs and intermediates and executed cGMP campaigns. Their facility is first-class and is supported by an excellent analytical chemistry group and a robust quality assurance system. What sets GlycsoSyn apart is they do more than just 'fee-for-service' work; they commit to a project as if it were their own.”

-Dr Tom McCarthy, CEO, SpinIfex